Soteria Biotherapeutics Announces Scientific Advisory Board

SAN FRANCISCO, Nov. 12, 2020 /PRNewswire/ -- Soteria Biotherapeutics, Inc. ("Soteria"), a privately-held, immuno-oncology company focused on developing a next generation of conditionally active bispecific t-cell engaging antibodies to treat cancer patients with solid tumors, today announced the formation of a scientific advisory board to help guide the company's early stage research and development.

"The advice and guidance from this distinguished group of scientists, clinicians and drug developers from world renowned academic institutions, big pharma and relevant immuno-oncology companies, will be invaluable to Soteria," said Kristine Ball, Chief Executive Officer of Soteria. "We look forward to working with this talented scientific advisory board as we build our early pipeline of small molecule controlled bispecific t-cell engagers and expand our small molecule switch platform."

Members of the Soteria Scientific Advisory Board include:

    --  Jim Wells, PhD, Soteria Co-founder and Chair of Scientific Advisory
        Board; Professor of Pharmaceutical Chemistry at UC San Francisco
        ("UCSF"); Investigator in the CZ Biohub and Hellen Diller Family
        Comprehensive Cancer Center; member of the National Academy of Sciences;
        formerly founding scientist in Genentech's protein engineering
        department; expertise in protein and antibody engineering
    --  Mike Briskin, PhD, Chief Scientific Officer of Phenomic AI; Chair of
        Obsidian Therapeutics Scientific Advisory Board; formerly founded Jounce
        Therapeutics and served as VP of Discovery Research; expertise in
        immuno-oncology therapeutics discovery and T cell trafficking
    --  Brian Daniels, MD, Partner at 5AM Ventures; formerly Senior Vice
        President of Global Development and Medical Affairs at Bristol Myers
        Squibb; expertise in therapeutics discovery and development
    --  Lawrence Fong, MD, Distinguished Professor in Cancer Biology and
        Director of the Cancer Immunotherapy Program at UCSF; Co-director of the
        Parker Institute for Cancer Immunotherapy at UCSF; Co-leader of the
        Cancer Immunology Program in the Helen Diller Family Comprehensive
        Cancer Center; expertise in cancer immunotherapy
    --  Peter Kim, PhD, Professor of Biochemistry at Stanford University School
        of Medicine; member of the National Academy of Sciences; formerly
        President of Merck Research Laboratories; expertise in therapeutics
        discovery and development
    --  Henry Lowman, PhD, Advisor and former Executive Vice President of R&D at
        Triphase; formerly Chief Scientific Officer at CytomX; formerly Director
        of Genetech's antibody engineering department; expertise in antibody
        discovery and development
    --  Arthur Weiss, MD, PhD, Distinguished Professor of rheumatology, of
        medicine, and of microbiology and immunology at UCSF; Investigator,
        Howard Hughes Medical Institute; member of the National Academy of
        Sciences; Co-founder of Nurix; expertise in immunology, T cell biology,
        and signal transduction

About Soteria Biotherapeutics Inc.

Soteria is developing a next generation of conditionally active bispecific t-cell engaging antibodies to treat cancer patients with solid tumors. Soteria's highly innovative T-LITE(TM) platform provides small molecule-dependent activation of bispecific antibody therapies, enabling safer and more efficacious treatments through pulsatile activity, reduced side effects and higher dosing. T-LITEs incorporate a small molecule-controlled switch into a conventional bispecific t-cell engaging antibody which enables precise on/off control over the timing and magnitude of redirected T-cell cytotoxic activity. Soteria was founded in 2018 with technology licensed from UC San Francisco and is based in San Francisco, California.

View original content:http://www.prnewswire.com/news-releases/soteria-biotherapeutics-announces-scientific-advisory-board-301171474.html

SOURCE Soteria Biotherapeutics